Eric K. Singhi: Great to see this option approved for our patients with Exon 20 Group insertions

Eric K. Singhi, Thoracic Medical Oncologist and Assistant Professor at the MD Anderson Cancer Center, recently shared a post on X/Twitter:

“Great to see this option approved for our patients with Exon 20 Group insertions.
Optimizing tolerance for patients on amivantamb remains a challenge (rash can be difficult to manage and can require dermatology help).

Still eagerly awaiting data from small molecule TKIs.”

Quoting Oncology Brothers‘ post:

“Amivantamab now FDA Oncology approved for mNSCLC Exon20 based off PAPPILON in 1L w/ chemo:

– PFS 11.4mos w/Ami vs 6.7mos chemo (HR: 0.40)
– ORR in 73% vs 47%
– OS favoring Ami (HR: 0.67)
– 7% Ami because of AEs
– New SoC/Practice Changing”

Source: Eric K. Singhi/X